Omalizumab treats multi-food allergy better than oral immunotherapy NIH News Release
High rate of oral immunotherapy side effects in NIH trial explains superiority of omalizumab. High rate of oral immunotherapy side effects in NIH trial explains superiority of omalizumab. Read More NIH News Release
Omalizumab treats multi-food allergy better than oral immunotherapy NIH News Release Read More »
